The Journal of the Association of Physicians of IndiaOct 22, 2026

Healthcare Professionals' Views on Newer Weight Loss Drugs Semaglutide and Tirzepatide in South Asia

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Oct 23, 2026

Abstract

Obesity contributes significantly to metabolic diseases and economic burdens in South Asia.

New antiobesity medications like semaglutide and tirzepatide show promising efficacy.
High costs of these medications may limit their accessibility in low- and middle-income countries.
Limited familiarity among healthcare professionals could hinder the adoption of these treatments.
Concerns regarding the safety of antiobesity medications exist among healthcare providers.

Simplified

Obesity has reached epidemic proportions in South Asia, contributing significantly to metabolic diseases and economic burdens. Newer antiobesity medications (AOMs), such as semaglutide and tirzepatide, show promising efficacy but face barriers such as high costs and limited familiarity among healthcare professionals (HCPs) in low- and middle-income countries (LMICs). This study explored perceptions, prescribing practices, efficacy, safety concerns, and barriers to AOM use among HCPs managing obesity in South Asia.

Healthcare Professionals' Views on Newer Weight Loss Drugs Semaglutide and Tirzepatide in South Asia

Abstract

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief